Neurology in Maine

FHC, Inc. is a specialized medical device manufacturer based in Bowdoin, Maine, founded in 1970. The company focuses on neuroscience and neurosurgery solutions, particularly cranial microtargeting and neuromodulation. FHC designs and manufactures microelectrodes, electrode positioning systems, stereotactic platforms, and surgical planning software for both clinical and research applications. Their clinical product line includes the Guideline 5 Neuromodulation System, STarFix Stereotactic Platforms, STar Microdrive System, and WayPoint Navigation software for surgical planning. The research division offers NeuroCraft microelectrodes and insertion tubes for neurophysiology studies. FHC's solutions support therapeutic interventions including deep brain stimulation, ablation, resection, and treatment of movement disorders such as Parkinson's Disease, epilepsy, dystonia, and essential tremor. The company also provides stereoelectroencephalography (SEEG) equipment and operates Greenville Neuromodulation Services for DBS research and surgeon training. With approximately 170 employees and estimated annual revenue of $42.6 million, FHC serves neurosurgical centers and research institutions globally.

MedRhythms is a digital therapeutics company developing prescription-grade neurotherapeutics that leverage rhythmic auditory stimulation (RAS) combined with sensors, software, and curated music to improve walking and mobility in patients with neurological disorders. The company's proprietary technology platform targets neural circuitry underlying gait impairments caused by stroke, Parkinson's disease, multiple sclerosis, and other neurologic conditions. MedRhythms currently markets two FDA-regulated digital therapeutic products: InTandem® for adults with chronic stroke-related walking deficits and MOVIVE® for Parkinson's disease patients, both available by prescription nationwide. The platform incorporates a collaboration with Universal Music Group to provide clinically curated, therapeutic music content individualized to each patient. The company was founded by Brian Harris, a board-certified Neurologic Music Therapist and pioneer in applying neuroscience-based music interventions at scale. MedRhythms operates dual service models: its digital therapeutics platform for remote and in-home use, and in-person clinical services through its Neurologic Music Therapy practice at Spaulding Rehabilitation Hospital. The technology is supported by over 30 years of published academic research demonstrating RAS efficacy in improving functional movement outcomes, with the company's clinicians having delivered over 75,000 hours of clinical experience using evidence-based music interventions.